Detail akcie ProQR Therapeutics online

Business Summary: ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Financial Summary: BRIEF: For the three months ended 31 March 2025, ProQR Therapeutics NV revenues increased 2% to EUR4.7M. Net loss increased 32% to EUR10.1M. Revenues reflect Revenue increase of 2% to EUR4.5M, Other Income increase of 6% to EUR222K. Higher net loss reflects Finance income and expense decrease of 7% to EUR455K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.09 to -EUR0.10.